Genocea Biosciences Inc (GNCAQ)

[jondoeuk]

It would be interesting to test the therapy in either HL or NHL with either LD and/or an anti-PD-1.

As for prostate, I know AUTL will move AUTO7 into the clinic next year. It has most of the enhancement 'modules' as AUTO6NG*, but will also locally secrete IL-12, the CAR has been designed to have improved activity in an acidic TME, and is able to target PSMA+ cells that have greatly reduced antigen expression.

* A safety switch, dnSHP2 (blocks PD-1, CTLA-4, TIGIT, 2B4 and BTLA signaling), chimeric cytokine receptor (to improve expansion and persistence), and a dnTGFßRII receptor.